Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression

Recruiting now · Not applicable

Conditions studied: Anxiety and Depression

In brief

This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=228) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and/or anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines/recommendations guided therapy (control intervention).

Key facts

Study ID

NCT06853587

Run by

University of Calgary

People needed

228

Starts

2025-02-11

Expected to finish

2027-12-01

Last updated by the study team

2026-06-22

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 12-17
• Depression and/or anxiety as the primary concern, confirmed by the treating physician
• Intention to start a new SSRI
• English fluency

You may not qualify if…

• Co-occurring obsessive compulsive disorder, psychosis, bipolar disorder, eating disorder, autism spectrum disorder, fetal alcohol spectrum disorder, or intellectual disability
• History of non-response to 3 or more SSRI medications as confirmed by the treating physician
• Brain stimulation-based therapy initiated within 8 weeks of referral, or plans to initiate/change brain stimulation during study participation
• History of liver or hematopoietic cell transplant
• History of CYP2B6, CYP2C19, or CYP2D6 testing

Where it is running

• University of Calgary — Calgary, Alberta, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.